Two secretagogues, two receptors
CJC-1295 and Ipamorelin are both classified as growth-hormone (GH) secretagogues, meaning that in the published preclinical literature they are described as compounds that stimulate the somatotroph cells of the anterior pituitary to release growth hormone. Despite sharing this broad category, the two peptides are structurally unrelated and act through entirely separate receptor systems. This distinction is the central reason they are frequently examined side by side in research contexts.
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) and engages the GHRH receptor. Ipamorelin is a synthetic pentapeptide that behaves as a selective agonist of the ghrelin receptor, also known as the growth-hormone secretagogue receptor (GHS-R). Because these are two different receptor targets converging on the same downstream axis, the peptides are often studied as complementary rather than interchangeable tools. This article compares them at the level of molecular identity, receptor pharmacology and how they are handled for laboratory research, without making any therapeutic, dosing or performance claims.
What CJC-1295 is
CJC-1295 is a modified peptide based on the first 29 amino acids of native GHRH (the GHRH(1-29) fragment, sometimes referred to in the literature as sermorelin-like sequences). It carries amino-acid substitutions intended to improve stability against enzymatic degradation relative to the unmodified GHRH fragment. In mechanistic terms, it is documented as binding the GHRH receptor on pituitary somatotrophs, the same receptor family engaged by endogenous GHRH.
An important and often-confused point is that CJC-1295 exists in two distinct forms. One form incorporates a Drug Affinity Complex (DAC), a moiety designed to bind albumin and extend the molecule's circulating presence. The other form omits this complex and is commonly labelled CJC-1295 without DAC, or Modified GRF (1-29), frequently abbreviated Mod GRF 1-29. The two share the core GHRH-analogue sequence and receptor target but differ in the presence or absence of the DAC modification. Research materials and reference documents should always specify which variant is under discussion, as they are not the same compound.
What Ipamorelin is
Ipamorelin is a synthetic pentapeptide, meaning it is composed of five amino-acid residues. It is described in the literature as a selective agonist of the ghrelin receptor (GHS-R), the same receptor targeted by the endogenous hormone ghrelin and by other secretagogue compounds such as GHRP-6 and GHRP-2. Unlike GHRH-based analogues, Ipamorelin does not act at the GHRH receptor.
A recurring point in the research characterisation of Ipamorelin is its reported selectivity within the secretagogue class. Preclinical studies have examined its GH-releasing activity relative to its interaction with other endocrine pathways. As with any peptide discussed here, these observations belong strictly to a research and mechanistic framing; this article makes no claim about outcomes, benefits or suitability for any use in humans or animals.
Why the two receptor targets matter
The growth-hormone axis is regulated by more than one input. GHRH, acting at the GHRH receptor, and ghrelin, acting at the GHS-R, represent two parallel signalling routes that both feed into pituitary GH release. Because CJC-1295 mimics the GHRH arm and Ipamorelin mimics the ghrelin arm, the two compounds are frequently studied together as a way of engaging complementary pathways rather than a single one.
In the published preclinical literature on GH secretagogues, GHRH-receptor agonists and GHS-R agonists have been reported to interact in combined-exposure experiments, which is the mechanistic basis for why researchers pair a GHRH analogue with a ghrelin-receptor agonist. This is a description of receptor pharmacology and experimental design, not a recommendation. The comparison here is therefore not a ranking: the two peptides are not competitors on a single scale but tools that occupy different positions in the same regulatory system.
Molecular identity and handling
CJC-1295 and Ipamorelin differ markedly in molecular identity. CJC-1295 is a 29-residue GHRH analogue (with additional mass in the DAC form owing to the affinity complex), whereas Ipamorelin is a compact five-residue peptide. These structural differences influence their physical characterisation, including molecular weight and the analytical methods used to confirm identity and purity.
For laboratory work, both are typically supplied as lyophilised (freeze-dried) powders. Analytical confirmation of a research peptide usually relies on techniques such as high-performance liquid chromatography (HPLC) for purity assessment and mass spectrometry (MS) for identity confirmation. Batch-specific documentation is what allows a researcher to link a physical vial to its analytical data. Sova Peptides supplies both CJC-1295 and Ipamorelin for research purposes with batch-linked Certificates of Analysis, so that the identity and purity data correspond to the specific lot received.
Summary of the comparison
Placed side by side, the two peptides can be summarised without any superiority judgement. CJC-1295 is a GHRH analogue acting at the GHRH receptor and exists in DAC and no-DAC (Mod GRF 1-29) forms. Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist and is a pentapeptide. They share the broad classification of GH secretagogue but reach it through different molecular routes.
Their frequent joint study reflects the complementary nature of the GHRH and ghrelin-receptor pathways within the somatotropic axis, not a claim that either is preferable. Any account of these compounds should remain at the level of receptor mechanism and published characterisation, which is the framing this article has kept throughout.
Research-use disclaimer
All information presented here is provided for educational and research-reference purposes only and describes mechanism and published preclinical literature. Nothing in this article constitutes medical, therapeutic, dosing or administration advice, and no health, clinical or performance benefit is claimed or implied.
CJC-1295 and Ipamorelin are supplied strictly as research materials and are not intended for human or veterinary use, diagnosis, treatment or consumption. They are not medicines and have not been approved for any therapeutic application. Researchers are responsible for handling these compounds in accordance with all applicable laws, institutional policies and safety requirements in their jurisdiction.
Frequently asked
What is the core difference between CJC-1295 and Ipamorelin?
They act on different receptors. CJC-1295 is a GHRH analogue that engages the GHRH receptor, while Ipamorelin is a pentapeptide that acts as a selective agonist of the ghrelin receptor (GHS-R). Both are classified as growth-hormone secretagogues but reach that classification through separate pathways.
What does the DAC versus no-DAC distinction mean for CJC-1295?
CJC-1295 exists in two forms. One incorporates a Drug Affinity Complex (DAC) designed to bind albumin and extend its circulating presence; the other omits it and is commonly called CJC-1295 without DAC or Modified GRF (1-29). Both share the GHRH-analogue sequence and receptor target but differ in the DAC modification.
Why are these two peptides studied together?
Because they engage complementary arms of the growth-hormone axis. CJC-1295 mimics the GHRH input and Ipamorelin mimics the ghrelin input, so pairing them lets researchers examine two parallel signalling routes rather than a single receptor pathway.
Is Ipamorelin a GHRH analogue?
No. Ipamorelin does not act at the GHRH receptor. It is a synthetic pentapeptide that acts on the ghrelin receptor (GHS-R), the same receptor targeted by endogenous ghrelin and related secretagogue peptides.
Does this comparison indicate one peptide is better than the other?
No. The comparison is at the level of receptor pharmacology and molecular identity. The two occupy different positions in the same regulatory system and are described as complementary research tools, with no superiority claim made or implied.
What is Mod GRF 1-29?
Mod GRF 1-29 is another name for CJC-1295 without DAC. It refers to the modified GHRH(1-29) fragment carrying stabilising amino-acid substitutions but lacking the Drug Affinity Complex present in the DAC form.
How is the identity and purity of these research peptides confirmed?
Analytical characterisation typically uses high-performance liquid chromatography (HPLC) for purity and mass spectrometry (MS) for identity confirmation. Batch-linked Certificates of Analysis allow a specific vial to be matched to its corresponding analytical data.
Are CJC-1295 and Ipamorelin intended for human use?
No. Both are supplied strictly as research materials for laboratory use only. They are not medicines, are not approved for any therapeutic application, and are not intended for human or veterinary use, diagnosis, treatment or consumption.